Company
Translate Bio, Inc.
Headquarters: Lexington, MA, United States
Employees: 122
CEO: Mr. Ronald C. Renaud Jr., MBA
Market Cap
$532,751
USD as of July 1, 2025
Translate Bio, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. As of September 13, 2021, Translate Bio, Inc. operates as a subsidiary of Sanofi.
Financials
| Last Financial Reports Date | June 30, 2024 |
| Revenue TTM | $15.6 M |
| EBITDA | $-28,074,000 |
| Gross Profit TTM | $7.5 M |
| Profit Margin | -292.59% |
| Operating Margin | -328.48% |
| Quarterly Revenue Growth | -71.90% |
Stocks & Indices
Translate Bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TBIO wb_incandescent